Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Highlights•Hsp90 is a molecular chaperone that modulates the function of many client
proteins.•Morphogenesis is an important Candida albicans virulence trait.•Hsp90 regulates …

Fungal infections due to Candida and Aspergillus species cause extensive morbidity and
mortality, especially among immunosuppressed patients, and antifungal therapy is critical to …

Invasive fungal infections are becoming an increasingly important cause of human mortality
and morbidity, particularly for immunocompromised populations. The fungal pathogens …

Tolerance to antifungal drug concentrations above the minimal inhibitory concentration
(MIC) is rarely quantified, and current clinical recommendations suggest it should be …

Candida is the most implicated fungal pathogen in the clinical setting. Several factors play
important roles in the pathogenesis of Candida spp. Multiple transcriptional circuits …

Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related
with anidulafungin. It is considered the first molecule of the new generation of long-acting …

Candida albicans is the leading cause of fungal infections; yet, complex genetic interaction
analysis remains cumbersome in this diploid pathogen. Here, we developed a CRISPR …

Human fungal pathogens are the causative agents of devastating diseases across the
globe, and the increasing prevalence of drug resistance threatens to undermine the already …